We evaluate the selection of patient, safety, feasibility, and the early results of LAAC with WMF in a single hospital without on-site cardiac surgery backup.
mEthods
From December 2015 to February 2016, percutaneous LAAC (WMF) was performed in a total of 16 patients, including one patient who had undergone two times of procedures. The implantation procedure was performed by the same experienced investigators under transesophageal echocardiography (TEE) guidance.
This was a retrospective study designed to investigate the safety and efficacy of LAAC with WMF. Patients were over 18 years with documented chronic or paroxysmal nonvalvular AF (NVAF) and had an estimated life expectancy of at least 2 years. 
Patient selection Inclusion criteria

Device implantation
The device implantation procedure is the same with WM which was described previously in detail. [6] Patients were staying in hospital overnight and discharged the next day after transthoracic echocardiography examination to the exclusion of pericardial effusion. TEE follow-up was repeated at 45 days and 6 months, to make sure that there was no thrombus or leakage around the device.
Medical treatment
When there was no contraindication of warfarin, anticoagulation therapy with warfarin was given for 45 days if there was no thrombus or leakage around the device. This was confirmed by TEE and then dual antiplatelet therapy (DAPT) with Aspirin (100mg/day) and Clopidogrel (75mg/day) given for up to 6 months after implantation. This was then followed by oral administration of 100mg/day Aspirin.
Patients with contraindication for warfarin were under the following therapy: Enoxaparin sc. 0.01 mg/kg twice daily for 45 days. If no evidence of thrombus or leakage from TEE at 45-day follow-up then one initiated a therapy of 100 mg aspirin plus 75 mg clopidogrel once daily until 6 months after implantation, and finally followed by 100 mg aspirin.
In case of a peridevice leak flow >5 mm on follow-up TEE, the initial anticoagulation regimen (either warfarin or aspirin/clopidogrel) was prolonged for another 6 weeks followed by TEE.
Endpoints
The primary endpoint was successful implantation of the WMF device. The secondary endpoints included complications during device implantation and the occurrence of adverse events within the whole follow-up period. Successful sealing of the LAA was determined by TEE, by no leak flow, or with minimal leak (gap <5 mm). Sealing was confirmed at three different time points: at the end of the implantation procedure, after 45 days, and after 6 months. Major adverse events were defined as death, stroke, transient ischemic attack (TIA), systemic embolism, device thrombosis, and major bleeding requiring invasive treatment or blood transfusion.
Statistical analysis
Estimated frequencies of event occurrence are expressed as percentage or rate. Continuous variables are summarized as mean ± standard deviation. 
rEsults
LAAC was performed using WMF in 16 NVAF patients mostly with long-term OAC contraindication. Mean age was 75 ± 5 years, and 70.6% were male. Hypertension, diabetes, and stroke before operation were present in 87.5%, 25%, and 18.8%, respectively. Mean CHADS2, CHA2DS-VASc, and HASBLED scores were 3.0 ± 1.1, 4.0 ± 15, and 3.0 ± 1.2, respectively [ Table 1 ].
The success rate of device implantation was 100% and no severe major procedural complications were observed.
During the procedure, no cases needed to change different size, seven cases (35.3%) needed to recapture, and gap was discovered in one case (5.9%) [ Table 2 ].
TEE was performed in the first 6 weeks and 6 months after LAAC, 100% patients finished 6 weeks follow-up. No device-related death was recorded; no ischemic stroke/TIA was observed. However, three cases experienced device dislocation. The WMF devices were out of left appendage, two at descending aorta and one at ascending aorta. Fortunately, we found all of the lost devices and successfully captured the device with Caesar grasping forceps system (COOK Medical, Winston-Salem, Ireland) via arteria femoralis (18F sheath). Two of the dislocation cases were implanted Watchman device instead, and one was implanted another smaller WMF (from 27 mm to 24 mm). Twelve patients have already accepted 6 months TEE; unfortunately, there was one patient with thrombosis on the WMF surface [ Table 3 ].
discussion
Currently, OAC therapy is the traditional way to prevent stroke in NVAF patients; however, more than half of the patients do not receive this therapy for various reasons. [4] The main caution for prescription OAC is afraid of bleeding particularly cerebral and gastrointestinal bleeding. In NVAF, over 90% thrombus was found in the LAA; [7] it is reasonable to seal the LAA to prevent thrombus formation.
WM has the most adequate evidence in stroke prevention of NVAF. [8, 9] WMF is the upgrading product of WM.However, until now, we have few experiences about this device. WM and WMF have the similar design idea, but WMF has some key improvements according to the manufacturer's instruction. WMF is more flexible and has a flat top to prevent perforation of LAA wall during the release process, and two rows of hooks are placed to fix the device more firmly. Theoretically, WMF will be easy and safe to be implanted; however, now, it has some troubles in the real world.
Three of 17 cases experienced unexpected dislocation in 6 weeks after the procedure out of peri-intervention. The main operator of our center is skillful to use WM, so we think that there is no relationship between the operate skills. In fact, we do not understand the real reason of dislocation. Maybe, some factors should be carefully considered.
We noticed that one of the three patients suffering from device dislocation accepted another operation by implanting the second WMF smaller than the first one. It indicates that compression ratio cannot be too large for the WMF. The The WMF is short, so the demand of LAA's depth is so strict when implantation, but the device capacity center may move to the orifice of the LAA. As a result, dislocation may happen.
WMF has two rows of hooks, it is more than WM, but hooks' angle and length have many differences. Hence, hooks may not work well and fixed firmly.
What's more, the flexibility of the WMF is better than WM, but it needs a long time to release device to a final posture during the operation. We doubt that WMF may still have a minigesture change after the tractive test and the mini change may cause the dislocation.
In our research, one of 17 cases occurred device surface thrombosis; in fact, we speculate that it might be a result of small possibility event. Further study with a large of sample size should be implemented to draw a conclusion.
According to our experience, the device characters including the length, flexibility and the hooks' placed way may need some improvements.
Study limitations
This study is a retrospective and small scale with limited 17 cases, which is our main limitation.
conclusions
LAAC with WM is a safe and effective therapy to prevent stroke in NVAF patients. The WMF is the new upgrading product of the WM device, but not the final device. It still needs accumulating clinical experience with WMF, and the device dislocation should also be alerted.
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